In urothelial carcinoma, a higher proportion of Firmicutes DNA in serum EVs correlates with reduced tumor-infiltrating T cells, decreased T cell activation, and poorer prognosis in patients treated with anti-programmed cell death protein 1 (PD-1) therapy [20]. This evidence concerns the gene PDCD1 and urothelial carcinoma.